Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.62 |
| ▸ | GLO1 | Q04760 | 5/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 2/20 | 0.38 |
| ▸ | FNTB | P49356 | 2/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | GLP1R | P43220 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3388445 | 0.91 | PTGS1 (0.63) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL28180347 | 0.90 | PTGS1 (0.62) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL3798423 | 0.90 | PTGS1 (0.62) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL993265 | 0.89 | PTGS1 (0.69) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL2048450 | 0.88 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL28851364 | 0.88 | PTGS1 (0.59) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL28862930 | 0.87 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL1332941 | 0.87 | PTGS1 (0.71) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL8933698 | 0.87 | NOD1 (0.58) | PTGS1GSTK1GLO1NOD1FNTA | |
| SCHEMBL3796646 | 0.87 | NOD1 (0.58) | PTGS1GSTK1GLO1NOD1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700560-B2 | Inactivators and bivalent inhibitors of glyoxalase I and methods of inhibiting tumor growth | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2010-04-20 | — | — | US | disclosed |
| US-20070129311-A1 | Inactivators and bivalent inhibitors of glyoxalase i and methods inhibiting tumor growth | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129311-A1 | Inactivators and bivalent inhibitors of glyoxalase i and methods inhibiting tumor growth | GLS, GLO1, GLRX3 | PTGS1 324/4885GSTK1 27/4885GLO1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.